Operating cash flow was -$12.4M in 2026Q2 and negative in every reported quarter, with free cash flow margins as low as -154.6%, indicating that cash burn persists independent of headline revenue movements and that the revenue spike has not yet translated into cash generation.
ProQR Therapeutics N.V. (PRQR) cash flow statement — 13-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Cash from Operations | -49.14M | -52.79M | -36.39M | 21.55M | -68.51M | -26.01M | -47.06M | -43.97M | -30.68M | -34.95M | -34.22M | -24.23M | -14.46M | -2.33M |
| Operating CF Margin % | - | -345.53% | -192.5% | 330.8% | -1906.18% | -1948.46% | -4573.38% | -2274.7% | -620.97% | 2285.87% | -1499.61% | -257.6% | -4618.85% | - |
| Operating CF Growth % | -138.5% | -45.06% | -268.89% | 131.45% | -163.37% | 44.73% | -7.03% | -43.31% | 12.21% | -2.13% | -41.22% | -67.61% | -519.94% | - |
| Net Income | -42.4M | -42.18M | -27.76M | -27.73M | -64.2M | -60.8M | -46.61M | -56.75M | -37.09M | -43.52M | -39.12M | -20.83M | -12.13M | -3.25M |
| Depreciation & Amortization | 2.76M | 2.7M | 2.76M | 2.51M | 2.52M | 2.33M | 2.35M | 2.05M | 992K | 1.06M | 1.25M | 480K | 126K | 24K |
| Stock-Based Compensation | 3.77M | 4.01M | 2.54M | 3.11M | 2.87M | 6.22M | 7.84M | 9.11M | 3.22M | 4.02M | 2.45M | 1.21M | 646K | 41K |
| Deferred Taxes | 1K | 19K | -197K | -78K | 96K | 117K | 124K | 132K | 102K | 145K | 236K | 441K | 142K | 13K |
| Other Non-Cash Items | 1.76M | 74K | -474K | -5.21M | -4.8M | 1.11M | -5.29M | -210K | 792K | 3.17M | -470K | -6.17M | -4.33M | 14K |
| Working Capital Changes | -15.26M | -17.42M | -13.26M | 48.96M | -4.99M | 25.01M | -5.47M | 1.69M | 1.29M | 164K | 1.43M | 637K | 1.09M | 829K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.15M | -1.02M | -4.07M | 4.28M | -702K | -425K | -924K | -580K | -312K | -121K | -2.54M | -1.32M | -1.23M | -137K |
| Capital Expenditures | -1.15M | -1.02M | -1.42M | -1.37M | -708K | -484K | -924K | -580K | -312K | -121K | -2.54M | -1.32M | -1.23M | -137K |
| CapEx % of Revenue | 6.21% | 6.68% | 7.5% | 21.05% | 19.7% | 36.25% | 89.8% | 30.01% | 6.31% | -7.91% | 111.26% | 14.07% | 393.93% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -2.65M | 5.65M | 6K | 59K | 0 | 0 | 0 | 0 | 0 | -28K | 0 | 0 |
| Cash from Financing | 48.04M | -1.84M | 70.28M | -2.27M | -30.89M | 136.83M | 14.5M | 50.2M | 88.65M | 26.64M | 357K | 1.62M | 119.88M | 6.35M |
| Debt Issued (Net) | -1.97M | -1.91M | -1.58M | -2.63M | -45.05M | 26.84M | 13.77M | 1.46M | 1.4M | 951K | 355K | 1.61M | 1.63M | 3.33M |
| Equity Issued (Net) | 50.02M | 69K | 71.64M | 0 | 14.12M | 108.48M | 0 | 48.55M | 84.19M | 25.68M | 0 | 0 | 118.25M | 3.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -8.36K | 0 | 223K | 354K | 34K | 1.52M | 735K | 193K | 870K | 4K | 2K | 14K | 0 | 0 |
| Net Change in Cash | -3.29M | -56.99M | 30.48M | 24.15M | -92.75M | 111.69M | -36.11M | 6.37M | 57.48M | -11.1M | -35.66M | -17.87M | 108.61M | 3.88M |
| Free Cash Flow | -50.29M | -53.81M | -37.81M | 20.18M | -69.22M | -26.5M | -47.98M | -44.55M | -30.99M | -35.07M | -36.76M | -25.56M | -15.69M | -2.47M |
| FCF Margin % | -270.78% | -352.21% | -200.01% | 309.75% | -1925.88% | -1984.72% | -4663.17% | -2304.71% | -627.28% | 2293.79% | -1610.87% | -271.67% | -5012.78% | - |
| FCF Growth % | -17.1% | -42.32% | -287.4% | 129.15% | -161.23% | 44.78% | -7.71% | -43.74% | 11.63% | 4.59% | -43.84% | -62.88% | -535.48% | - |
| FCF per Share | -0.46 | -0.51 | -0.46 | 0.25 | -0.97 | -0.41 | -0.96 | -1.09 | -0.91 | -1.38 | -1.57 | -1.09 | -0.71 | -0.11 |
| FCF Conversion (FCF/Net Income) | 1.19x | 1.30x | 1.31x | -0.77x | 1.06x | 0.43x | 1.01x | 0.77x | 0.83x | 0.80x | 0.88x | 1.16x | 1.19x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying PRQR stock.
ProQR Therapeutics N.V. (PRQR) generated $-52.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
ProQR Therapeutics N.V. (PRQR) reported negative free cash flow of $53.8M in 2025, indicating capital requirements exceeded cash from operations.
ProQR Therapeutics N.V. (PRQR) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Cash Burn Exceeds Reported Losses
According to the reported cash flow data, PRQR's operating cash flow was negative in every one of the ten quarters, with the ratio of operating cash flow to net income ranging from 0.70 to 2.32, indicating cash losses that frequently run ahead of or alongside accounting losses.
Because net income and operating cash flow are both negative in each period, the ratio is mechanically less informative than the absolute gap, which in several quarters such as 2024Q2 and 2026Q2 shows operating cash outflows larger than reported losses. This pattern suggests working capital movements and collaboration timing may be amplifying cash consumption relative to earnings. Investors should monitor whether the 2026Q2 revenue spike converts into actual cash receipts, since the absence of such conversion would widen the cash gap further.
Free Cash Flow Deeply Negative Throughout
As reported in the cash flow statements, PRQR's free cash flow was negative across all ten quarters, reaching -$16.0M in 2025Q1 and -$12.7M in 2026Q2, with free cash flow margins frequently falling below -100% in periods of low revenue.
The persistence of negative free cash flow across a full decade indicates that the business has not yet reached a level of operating scale capable of funding its research spend internally. The extreme negative margins in quarters such as 2026Q2 reflect the small revenue base relative to fixed cash outlays rather than a deteriorating cost structure alone. Without a sustained revenue step-up, the trajectory implies continued reliance on external balance sheet resources.
Minimal Capital Intensity Despite Spikes
Based on reported figures, PRQR's capital expenditure remained small in absolute terms, between roughly $0.1M and $0.7M per quarter, though the capex-to-revenue ratio spiked to 16.4% in 2024Q1 when revenue was comparatively low.
Low absolute capex relative to the cash burn indicates that the cash drain is driven primarily by operating expenses, chiefly research and development, rather than by physical asset investment. The elevated capex-to-revenue readings in periods of weak revenue reflect denominator effects rather than heavy investment programs. This suggests the company's capital requirements are largely tied to clinical and operating spend rather than to facilities.
Working Capital Swings Drive Volatility
As reported in the working capital line, PRQR's working capital change ranged from a $9.2M outflow in 2024Q1 to a $1.1M inflow in 2024Q3, with several quarters showing large swings that appear to account for much of the quarter-to-quarter variance in operating cash flow.
The magnitude of working capital movements relative to reported net losses suggests timing of collaboration receivables and payables is a material driver of reported operating cash flow. Such swings indicate that quarterly cash results may be poorly indicative of underlying run-rate burn. Investors would benefit from examining the composition of these movements before drawing conclusions about the sustainability of cash generation.
Revenue Spike May Not Reflect Cash
Based on reported figures, the 2026Q2 revenue jump may prove non-recurring, and the quarter still recorded operating cash flow of -$12.4M, suggesting headline revenue gains have not translated into cash generation.
A bullish reading of the latest revenue increase would need to show collections following recognition, which the cash data does not yet demonstrate. The data does not disclose the nature of the collaboration income, so its durability cannot be assessed from these figures alone. Until operating cash flow turns sustainably positive, the revenue improvement should be treated as analytically uncertain.